More than 63,000 Americans died of opioid drug overdoses last year, more than the number killed in car crashes.
On Wednesday, the FDA approved the first drug designed to treat the symptoms of opioid withdrawal, which can be painful and hook users in a potentially deadly cycle of addiction.
The drug is called Lucemyra and is made by pharmaceutical company US WorldMeds.

Deaths from drug overdoses often start with a last-ditch attempt to subdue painful, flu-like symptoms.

Among the signs that someone has suddenly quit taking a painkiller like OxyCodone or Vicodin: nausea, vomiting, shakiness, and pervasive feelings of panic and depression.

Together, those symptoms constitute withdrawal from opioids. Until today, there were no approved drugs specifically designed to treat that condition, which left few options for people who had been taking the drugs. If they took more painkillers (or a cheaper illegal alternative like heroin), they risked overdose, addiction, and death.

But on Wednesday, the US Food and Drug Administration approved the first medication made expressly to treat signs of opioid withdrawal. The drug will be sold under the brand name Lucemyra by pharmaceutical company US WorldMeds, and its active ingredient is lofexidine. The compound stops the brain from getting flooded with the chemical transmitter that produces most of those flu-like withdrawal sensations.

Mark Pirner, the medical director of clinical research for US WorldMeds, told Business Insider the drug addresses an issue that’s central to the problem of opioid use disorder, or OUD.

“When people need to transition from one stage in their treatment for OUD into whatever comes next, withdrawal is a huge obstacle. If that happens and they can’t get through it, they’re lost,” Pirner said.

In clinical trials, lofexidine was pitted against a placebo and found to work better at curbing withdrawal symptoms. People who got it were also significantly more likely …read more

Source:: Business Insider


(Visited 3 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *